Maravai LifeSciences
- Market cap
- 1.11B
- P/E (TTM)i
- -14.02
- P/Bi
- 5.41
- EPSi
- -0.90
- Div yieldi
- 0.00%
- 52W posi
- 71%
Anonymous reader poll. Unscientific, not investment advice.
About Maravai LifeSciences
Maravai Lifesciences Holdings, Inc. engages in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm’s brands include TriLink BioTechnologies, Cygnus, Glen Research, and Alphazyme. It operates through the TriLink and Cygnus segments. The TriLink segment manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Cygnus segment sells biologic safety testing products and highly specialized analytical products for use in biologic manufacturing process development, including custom product-specific antibody and assay development services. It also operates through the following geographical segments: North America, Asia Pacific, Europe, the Middle East, and Africa, and Latin and Central America. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.
- Founded
- 2014
- CEO
- Mr. Bernd Brust
- Employees
- 435
- Headquarters
- San Diego, California, United States of America
- Fiscal year end
- 12-31
- Website
- maravai.com
Company profile
- Exchange
- US
- Symbol
- MRVI
- Market-cap rank
- #3116
- Listing date
- 2020-11-20
- Market cap
- 1.11B
- Float cap
- 762.35M
- Shares out
- 148.99M
- Float shares
- 102.60M
Sectors & themes
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.